Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek naar Buntanetap bij deelnemers met de ziekte van Parkinson

28 oktober 2026 bijgewerkt door: Annovis Bio Inc.

Een open-label klinische studie naar de langetermijnveiligheid van Buntanetap bij de behandeling van deelnemers met de ziekte van Parkinson

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Studie Overzicht

Gedetailleerde beschrijving

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Studietype

Ingrijpend

Inschrijving (Geschat)

500

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • Werving
        • University of Alabama at Birmingham
        • Contact:
        • Hoofdonderzoeker:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Verenigde Staten, 85351
        • Werving
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Hoofdonderzoeker:
          • Sara Dhanani, M.D.
        • Contact:
    • California
      • Fountain Valley, California, Verenigde Staten, 92708
        • Werving
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Hoofdonderzoeker:
          • Daniel Truong, M.D.
        • Contact:
          • Evan Moreno-Davis
          • Telefoonnummer: 714-378-5074
          • E-mail: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Verenigde Staten, 80113
        • Werving
        • Cenexel Rocky Mountain Clinical Research
        • Contact:
        • Hoofdonderzoeker:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Verenigde Staten, 06824
        • Werving
        • New England Institute for Clinical Research (Ki Health Partners)
        • Contact:
        • Hoofdonderzoeker:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Verenigde Staten, 33180
        • Werving
        • First Choice Neurology - Aventura Neurologic Associates
        • Hoofdonderzoeker:
          • Jonathan Cross, M.D.
        • Contact:
      • Daytona Beach, Florida, Verenigde Staten, 32117
        • Werving
        • Arrow Clinical Trials
        • Contact:
        • Hoofdonderzoeker:
          • David Billmeier, M.D.
      • DeLand, Florida, Verenigde Staten, 32720
        • Werving
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Hoofdonderzoeker:
          • Bruce Rankin, D.O.
        • Contact:
      • Miami, Florida, Verenigde Staten, 33172
      • Miami, Florida, Verenigde Staten, 33015
        • Nog niet aan het werven
        • Ezy Medical Research Co.
        • Contact:
      • Ocala, Florida, Verenigde Staten, 34470
        • Werving
        • Renstar Medical Research
        • Hoofdonderzoeker:
          • Annette Nieves, M.D.
        • Contact:
      • Tampa, Florida, Verenigde Staten, 33613
        • Werving
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Contact:
        • Hoofdonderzoeker:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Verenigde Staten, 32789
    • Georgia
      • Decatur, Georgia, Verenigde Staten, 30030
        • Werving
        • iResearch Atlanta
        • Contact:
        • Hoofdonderzoeker:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46256
        • Werving
        • Josephson Wallack Munshower Neurology, P.C.
        • Hoofdonderzoeker:
          • Kristi George, M.D.
        • Contact:
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • Werving
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Contact:
        • Hoofdonderzoeker:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Verenigde Staten, 48334
        • Werving
        • Quest Research Institute
        • Hoofdonderzoeker:
          • Aaron Ellenbogen, D.O.
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10019
        • Werving
        • Mount Sinai Hospital
        • Hoofdonderzoeker:
          • Joohi Jimenez-Shahed, M.D.
        • Contact:
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710
        • Werving
        • Duke Department of Neurosurgery
        • Hoofdonderzoeker:
          • Kyle Mitchell, M.D.
        • Contact:
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210
        • Werving
        • The Ohio State University Wexner Medical Center
        • Hoofdonderzoeker:
          • Zachary Jordan, M.D.
        • Contact:
    • Oklahoma
      • Tulsa, Oklahoma, Verenigde Staten, 74136
        • Werving
        • The Movement Disorder Clinic of Oklahoma
        • Contact:
        • Hoofdonderzoeker:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Verenigde Staten, 19090
        • Werving
        • Abington Neurology
        • Hoofdonderzoeker:
          • David Weisman, M.D.
        • Contact:
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29401
        • Werving
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Contact:
        • Hoofdonderzoeker:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Verenigde Staten, 38018
        • Werving
        • Neurology Clinic, P.C.
        • Contact:
        • Hoofdonderzoeker:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Verenigde Staten, 38157
        • Werving
        • Veracity Neuroscience LLC
        • Contact:
        • Hoofdonderzoeker:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Verenigde Staten, 78681
        • Werving
        • Central Texas Neurology
        • Contact:
        • Hoofdonderzoeker:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22903
        • Werving
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Hoofdonderzoeker:
          • Binit Shah, M.D.
        • Contact:
    • Washington
      • Spokane, Washington, Verenigde Staten, 99202
        • Werving
        • Inland Northwest Research
        • Hoofdonderzoeker:
          • Jason Aldred, M.D.
        • Contact:
    • Wisconsin
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Werving
        • Medical College of Wisconsin
        • Contact:
        • Hoofdonderzoeker:
          • Karen Blindauer, M.D.

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

40 jaar tot 85 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Experimenteel: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety of buntanetap
Tijdsspanne: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Tijdsspanne: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Tijdsspanne: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Tijdsspanne: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 januari 2026

Primaire voltooiing (Geschat)

1 september 2029

Studie voltooiing (Geschat)

1 november 2029

Studieregistratiedata

Eerst ingediend

26 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

9 december 2025

Eerst geplaatst (Werkelijk)

16 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

28 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren